SWISS AMI: Stem cells infusion after primary angioplasty

The trial enrolled 200 patients post AMI treated with successful PCI, with LVEF ≤45% randomized to placebo, to receive early (before 7 days) or late (after 7 days) stem cells infusion. Primary end point was LVEF at 4 months. At follow up, stem cells infusion, both early and late, did not improve LVEF, compared to placebo.

Conclusion: Stem cells infusion post PCI does not improve EF in patients with ventricular dysfunction. 

5_daniel_surder
Daniel Sürder
2012-11-06

Original title: Results of the Swiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (Swiss Ami) Trial

More articles by this author

PILOT trial: Pilot study of two levels of hypothermia in comatose survivors after out-of-hospital cardiorespiratory arrest.

Hypothermia is neuroprotective, because it reduces brain oxygen consumption in 6%, suppresses chemical reactions associated to reperfusion, reduces free radicals and mitochondrial damage. It...

TIME: Use and duration of bone marrow derived stem cells infusion for the treatment of post infarction ventricular dysfunction.

This study randomized 120 patients with acute myocardial infarction after successful primary angioplasty with a residual ejection fraction (LVEF) <45%. An intracoronary infusion with...

POSEIDON: Transendocardial infusion of autologous vs. allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy.

Safety and efficacy of autologous vs. allogeneic mesenchymal stem cells had not yet been compared. This trial randomized 30 patients with LV dysfunction due...

SCIPIO trial: Intracoronary infusion of autologous cardiac stem cells improve ventricular function.

This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy. It consecutively enrolled 37 patients with reduced...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...